A new book by Hedley Rees tackles a litany of pharma industry problems, including “eye-watering drug prices, shortages, litigation over damaging side effects, questionable marketing practices, economic adulteration, consent decrees, counterfeiting, patent games [and] price gouging”.
Rees says we should stop believing that medicines are different to all other products on sale in the market, because they are not. Science is an important component in bringing a medicine to the world, but it takes a healthy dose of engineering skills to get them there too, and the application of those skills is sadly lacking in pharma. The system for producing and supplying a medicine to market should be no different, he says, to an aero-engine, automobile or silicon chip. While the book is “uncompromising on facts and evidence”, it aims to offer a “practical solution” for the pharma industry, says the author. Taming The Big Pharma Monster by Speaking Truth to Power by Hedley Rees is published by Filament (London) on May 28, 2019. More information can be found at the author's website: pharmaflowltd.com
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.